Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989) disclosed its unaudited third-quarter financials for the nine-month period ended September 30, 2025. During the reporting period, operating revenue reached RMB 4.19 billion, showing a 3.09% increase compared to the same period in 2024. Net profit attributable to shareholders was reported at RMB 553.58 million, representing a 29.04% decrease year-on-year.

In the third quarter alone, operating revenue stood at RMB 1.38 billion, an 11.82% rise over the same period last year. Net profit attributable to shareholders grew by 13.14% to RMB 131.73 million. Meanwhile, net cash flows from operating activities totaled RMB 1.44 billion for the nine months, down 19.60% year-on-year.

The balance sheet showed total assets at RMB 17.13 billion, decreasing by 1.24% from the end of 2024. Notable changes included a rise in purchases of wealth management products and other short-term investments, as well as an expansion in prepayments, while construction in progress declined significantly due to completed project conversions. Long-term borrowings dropped, offset by a higher balance of non-current liabilities due within one year.

Management indicated the overall financial results were influenced by factors such as increased research and development expenses and changes in fair value from investments. The company has not provided forward-looking statements in this announcement.